NCT06714955View on ClinicalTrials.gov

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

January 21, 2025

Study Completion Date

March 3, 2025

Conditions
Non-diabetic Overweight or Obese
Interventions
DRUG

Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

Drug: BGM0504 Administered SC

DRUG

Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.

Drug: BGM0504 Administered SC

DRUG

Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.

Drug: Placebo Administered SC

Trial Locations (1)

21201

Pharmaron CPC, Inc, Baltimore

All Listed Sponsors
lead

BrightGene Bio-Medical Technology Co., Ltd.

INDUSTRY

NCT06714955 - Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects | Biotech Hunter | Biotech Hunter